Freemelt (FREEM) Q4 2022 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2022 earnings summary
13 Nov, 2026Executive summary
2022 marked commercial progress: eight Freemelt ONE systems sold in Europe and North America; industrial eMELT launched at the Frankfurt 3D-printing trade fair.
Revenue rose to SEK 37.3m from SEK 0.3m in 2021; the comparison period was June 17–December 31, 2021. Net loss was SEK 67.6m.
Development investment, including goodwill amortization, contributed to losses and negative operating cash flow; a Q1 2023 share issue raised SEK 66m before costs.
Financial highlights
Consolidated net sales were SEK 37.323m in 2022 vs SEK 0.302m in the shorter 2021 period; operating result was SEK -67.647m and net result SEK -67.603m.
Operating costs included SEK 53.287m of depreciation and amortization, including SEK 47.522m goodwill amortization; other operating income included a SEK 4.431m insurance recovery for shipping damage.
Cash from operations was SEK -29.442m; investing cash flow was SEK -16.626m, and cash declined to SEK 10.923m from SEK 56.904m.
Total assets were SEK 268.624m vs SEK 335.381m; equity was SEK 257.556m vs SEK 325.067m at year-end 2021.
Outlook and guidance
Priorities are growing Freemelt ONE sales through direct resources and resellers, targeting universities, research institutes and research-intensive industrial customers, especially in Europe and North America.
eMELT development will continue with selected strategic industrial partners, adapting Freemelt ONE technology for industrial production requirements and prioritized titanium and tungsten markets.
Positive cash flow depends on higher sales; system volumes and customer decision timing remain difficult to forecast, and further external capital may be needed if operations do not cover funding needs.
Latest events from Freemelt
- IPO funding backed industrial-system development as sales recovered from pandemic disruption.FREEM
Q4 2021 - Expansion into manufacturing targets a SEK 450–560bn market and EBITDA positivity by 2028.FREEM
Investor update - Order intake rose and cash flow turned positive despite lower sales, driven by new strategic deals.FREEM
Q2 2026 - Record sales, fusion breakthroughs, and China entry drive growth in AM and medtech.FREEM
Investor Update - Scaling up with 162% revenue growth, new funding, and global expansion in MedTech, defense, and fusion.FREEM
Investor update - Q1 net sales rose 116% YoY, with strong margins and key sector collaborations advancing.FREEM
Q1 2026 - Sales up 172% to SEK 54.5m, installed base up 40%, and strong growth in key sectors.FREEM
Q4 2025 - Q2 saw high activity, new orders, and strategic partnerships despite a wider loss.FREEM
Q2 2024 - First industrial eMELT sale, OEM order, and machine sales growth amid ongoing losses.FREEM
Q3 2024